Bone WizardryMEDICAL EDUCATION
⌘ KStart free
Back
On this page
0%
Skip to lesson

Pharmacology

Antidiabetic drugs. Match the mechanism to the person

Choose glucose-lowering treatment by insulin physiology, cardiovascular and kidney disease, weight goals, hypoglycemia risk, and acute illness precautions.

Two people have an A1C of 8.2%. One has albuminuric kidney disease and heart failure; the other has repeated low-glucose episodes while skipping meals. The same A1C does not create the same prescription. Begin with the person's risks, then choose a mechanism that fits.

Lower glucose safely, protect organs when evidence supports it, and make the treatment usable. Those goals overlap, but they are not interchangeable.

Choose an outcome before choosing a class

In type 2 diabetes, treatment depends on established atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, obesity, hypoglycemia risk, cost, and preferences. Metformin remains a useful, inexpensive starting option for many people, but it is not a compulsory checkpoint before prescribing an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit. Organ-protective treatment may be indicated independently of A1C and prior metformin use. Assess these conditions together rather than hiding them behind a sequence that stops after the first “yes.” [1]

Atherosclerotic disease

Choose a GLP-1 receptor agonist or SGLT2 inhibitor with demonstrated cardiovascular benefit, considering weight, kidney function and tolerability.

Heart failure or CKD

An SGLT2 inhibitor with relevant evidence is a key option. Additional glucose lowering may still be needed at low eGFR.

Weight or hypoglycemia priorities

GLP-1-based therapies can provide substantial weight reduction. Reduce reliance on insulin secretagogues when recurrent hypoglycemia is the main harm.

Do not translate every composite trial endpoint into a mortality claim. LEADER demonstrated cardiovascular benefit including fewer cardiovascular deaths with liraglutide. SUSTAIN-6 found fewer major adverse cardiovascular events with semaglutide, but cardiovascular death was similar between groups. DAPA-HF studied dapagliflozin in HFrEF with and without diabetes. These trials do not make every member of either class equivalent for every outcome. [9] [10] [11]

Kidney benefit is not exclusive to SGLT2 inhibitors. FLOW demonstrated a kidney outcome benefit with semaglutide in type 2 diabetes and CKD. Conversely, a medicine without proven organ-outcome benefit may still be a useful glucose-lowering choice when affordability, tolerability, frailty, or administration burden governs the decision. Glycemic treatment itself is not worthless. [12]

Marked symptomatic hyperglycemia, catabolic weight loss, suspected insulin deficiency, or hyperglycemic crisis changes the priority. Consider insulin when A1C exceeds 10%, glucose is very high, or symptoms suggest insulin deficiency. Type 1 diabetes requires insulin; noninsulin therapies do not replace basal insulin. [1]

Try it here · Checkpoint 1 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 1

A 59-year-old woman with type 2 diabetes and prior myocardial infarction has A1C 8.1% on metformin. BMI is 34 kg/m², eGFR 74 mL/min/1.73 m², and she has no HF, gastroparesis, or MTC/MEN2 history. Which addition has evidence for cardiovascular benefit and can help weight?

Show answer and explanations for case 1

  1. A. Liraglutide (Best answer)

    LEADER supports cardiovascular benefit in high-risk type 2 diabetes, and GLP-1 activity can reduce appetite and weight.

  2. B. Glipizide (Why this does not fit)

    It can lower A1C but adds hypoglycemia and weight gain without the requested cardiovascular outcome evidence.

  3. C. Sitagliptin (Why this does not fit)

    It is generally weight neutral and lacks the requested demonstrated cardiovascular benefit.

  4. D. Pioglitazone (Why this does not fit)

    Pioglitazone can cause weight gain and fluid retention, so it does not match her weight priority.

Takeaway: Select an agent with evidence for the desired outcome.

Case sources: [1] [10]

The beta cell explains hypoglycemia risk

Glucose metabolism increases beta-cell ATP. ATP-sensitive potassium channels close, the membrane depolarizes, voltage-gated calcium channels open, and insulin granules are released. Sulfonylureas bind the SUR1 component of the potassium channel and stimulate release even when glucose is low. Glipizide, glyburide and glimepiride therefore cause hypoglycemia and weight gain. Meglitinides such as repaglinide stimulate the same secretion pathway with shorter meal-related action; a missed meal still matters. [3] [1]

Two routes into insulin secretion

Secretagogue route

  1. Sulfonylurea closes the ATP-sensitive potassium channel.
  2. Depolarization opens calcium channels.
  3. Insulin release can persist despite low glucose.

Incretin route

  1. GLP-1 or GIP signaling amplifies the beta-cell response.
  2. The insulin response remains glucose dependent.
  3. Hypoglycemia risk is low when used without insulin or a secretagogue.

Both can increase insulin secretion. The discriminating feature is dependence on glucose, not simply the presence of more insulin.

Glipizide is mainly metabolized in the liver to largely inactive products. Do not explain every glipizide event as accumulation of active renal metabolites, which is a greater concern with glyburide. Nevertheless, CKD, older age, reduced intake and impaired counterregulation increase hypoglycemia risk with any secretagogue. A comparatively preferable drug is not risk-free. [3]

DPP-4 inhibitors such as sitagliptin and linagliptin prolong endogenous incretin activity. They provide modest glucose lowering, are generally weight neutral, and have low intrinsic hypoglycemia risk. Most need renal dose adjustment; linagliptin does not. Avoid combining a DPP-4 inhibitor with a GLP-1-based drug because the overlap adds little useful glucose lowering. Saxagliptin and alogliptin have specific heart failure warnings, so do not generalize one agent's profile to the entire class. Severe joint pain, bullous pemphigoid and pancreatitis precautions also deserve attention. [4] [19]

Lower glucose without forcing secretion

Metformin reduces hepatic glucose production and improves insulin sensitivity. Its biology involves multiple cellular and intestinal effects; “complex I inhibition explains everything” is too narrow. It does not directly force beta cells to secrete insulin, so hypoglycemia is uncommon alone. Weight is usually neutral or modestly reduced. GI upset often improves with a lower starting dose, slower titration, food, or an extended-release formulation. Long-term use can lower vitamin B12; evaluate unexplained anemia or neuropathy rather than assuming diabetic neuropathy. [2]

Metformin is contraindicated below eGFR 30 mL/min/1.73 m². Starting it at eGFR 30 to 45 is not recommended by the US label; continued treatment when renal function falls below 45 requires reassessment. Acute kidney injury, severe hypoperfusion, hypoxia, or substantial alcohol-related risk can favor withholding. Nausea with a normal lactate and normal perfusion is not itself metformin-associated lactic acidosis. Conversely, a high lactate during shock needs urgent assessment of both drug accumulation and the underlying illness.

Contrast precautions are selective. The US label recommends holding at or before iodinated contrast for eGFR 30 to 60, relevant liver disease, alcoholism or heart failure, or intra-arterial contrast, then reassessing renal function after 48 hours before restarting. Some radiology protocols are less restrictive for stable patients receiving IV contrast. Name the policy and risk factors; do not teach that every contrast study plus metformin causes acidosis. [2]

Thiazolidinediones, including pioglitazone and rosiglitazone, activate the nuclear receptor PPAR-gamma and improve insulin sensitivity through altered gene expression. Their onset is gradual. Fluid retention, weight gain and heart failure aggravation are major limitations. Initiating pioglitazone in NYHA III or IV heart failure is contraindicated, and symptomatic HF generally argues against its use. Fracture risk and bladder cancer precautions also influence selection. CKD alone is not an absolute contraindication, but fluid status matters. [8]

Rosiglitazone's regulatory history differed by region. FDA prescribing information continued to describe approved rosiglitazone-containing products after earlier restrictions were relaxed; saying it was universally withdrawn for cardiovascular harm is inaccurate. Historical approval does not establish current retail availability or erase the class heart failure warning. [18]

Acarbose delays carbohydrate digestion by inhibiting intestinal alpha-glucosidases. It mainly reduces postprandial glucose excursions. Carbohydrate reaching the colon is fermented, causing gas; diarrhea can also occur. If hypoglycemia develops because acarbose is combined with insulin or a secretagogue, use glucose rather than sucrose for oral rescue because sucrose digestion is delayed. [16]

Try it here · Checkpoint 2 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 9

A 55-year-old man taking metformin develops AKI after dehydration. eGFR is 24, lactate 1.8 mmol/L and bicarbonate 23 mEq/L. Which medication action is appropriate?

Show answer and explanations for case 9

  1. A. Hold metformin and reassess after renal recovery (Best answer)

    AKI warrants withholding because clearance can fall rapidly. The reported eGFR is also below the usual threshold of 30, although creatinine-based eGFR is unreliable during rapidly changing kidney function.

  2. B. Continue until lactate exceeds 5 (Why this does not fit)

    The renal contraindication is preventive; established lactic acidosis need not develop first.

  3. C. Continue at a reduced dose throughout the evolving AKI (Why this does not fit)

    Dose reduction is not an adequate substitute for a temporary hold during evolving AKI and dehydration.

  4. D. Replace metformin with glyburide as the safest renal option (Why this does not fit)

    Glyburide has a substantial prolonged hypoglycemia risk in renal impairment.

Takeaway: A normal lactate does not erase a renal contraindication.

Case sources: [2] [1]

Separate appetite signaling from renal glucose loss

GLP-1 receptor agonists such as liraglutide, dulaglutide and semaglutide enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite. Nausea and early satiety often accompany initiation or dose escalation. Persistent severe abdominal pain, dehydration or repeated vomiting needs assessment rather than automatic reassurance. Pancreatitis, gallbladder disease and severe gastrointestinal intolerance are clinically relevant precautions. [5]

Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2 under its label. The warning originates from rodent C-cell findings; human causation is not established. This is not a ban for every thyroid disorder. Rapid improvement in glycemia can accompany retinopathy worsening in susceptible patients, so pre-existing retinopathy needs monitoring. Products, doses and administration instructions differ; a suffix does not replace reading the label.

Tirzepatide activates both GIP and GLP-1 receptors. It does not directly activate the insulin receptor. Its delayed gastric emptying can reduce oral hormonal contraceptive effectiveness; the label advises a nonoral method or added barrier protection for four weeks after initiation and after each dose escalation. Weight and A1C effects depend on dose and population, so avoid promising a fixed percentage loss to everyone. [6]

SGLT2 inhibition at the proximal tubular cell

Tubular lumen
Filtered sodium and glucose approach the apical SGLT2 transporter.

Apical membrane
An SGLT2 inhibitor reduces sodium-glucose uptake into the tubular cell.

Downstream urine
More glucose remains in the filtrate; osmotic diuresis contributes to volume effects.

The transporter faces the lumen. The drug does not force pancreatic insulin secretion. [7]

Empagliflozin and dapagliflozin have heart failure and kidney indications. At low eGFR, glucose lowering diminishes even when organ protection remains valuable. Guidelines support appropriate SGLT2 treatment in CKD down to eGFR 20, but initiation thresholds depend on the specific product and indication. Correct volume depletion before starting and review diuretics. Genital candidiasis is a characteristic adverse effect; severe perineal pain, swelling, fever or systemic illness requires evaluation for Fournier gangrene, not routine antifungal treatment alone. [7] [1]

SGLT2-associated ketoacidosis can occur with glucose below 200 mg/dL because urinary glucose loss masks the expected hyperglycemia. Illness, fasting and insulin deficiency increase risk. Stop the drug and assess ketones and acid-base status if compatible symptoms develop. It is not routine type 1 diabetes therapy. [7]

Match insulin to time and protect against acute harm

Basal insulin suppresses between-meal and overnight glucose production. Glargine and degludec provide relatively flat background action; NPH has a more pronounced peak. Prandial lispro, aspart or other appropriate preparations cover food-related excursions. Correction insulin treats additional hyperglycemia. These roles are complementary. No basal preparation guarantees freedom from overnight lows. [1]

In hospital, use basal plus correction when intake is poor, and basal, prandial and correction components when eating if scheduled insulin is needed. Persistent hyperglycemia on correction-only treatment calls for reassessment. People with type 1 diabetes require basal insulin even while fasting. Hold metformin on the day of surgery under ADA guidance. Stop SGLT2 inhibitors three days before scheduled surgery, or four for ertugliflozin; restart only when clinically appropriate and intake has resumed. GLP-1 perioperative decisions are individualized because delayed gastric emptying affects aspiration risk. [14]

DKA treatment requires fluids, insulin and electrolyte monitoring. If potassium is below 3.5 mmol/L, replace it and delay insulin until it rises above 3.5. Insulin drives potassium into cells. Add dextrose when needed so insulin can continue clearing ketones without causing hypoglycemia. IV regular insulin is standard in many protocols, but the claim that it is the only insulin permitted IV is false; lispro U-100 has labeled IV use, whereas U-200 and basal formulations must not be substituted. Selected uncomplicated mild or moderate DKA can use a validated subcutaneous rapid-acting protocol. [13] [17]

For hypoglycemia, use oral glucose if alert and able to swallow; severe impairment requires glucagon or IV dextrose as appropriate. Repeated episodes can blunt warning symptoms through hypoglycemia-associated autonomic failure. Review doses, meals, activity and renal function, use glucose monitoring support, and arrange a period of hypoglycemia avoidance with individualized goals. Awareness may improve over several weeks. Recurrent secretagogue-related hypoglycemia requires observation and may need octreotide under toxicology guidance. [20][15]

Before adding a drug, check organ disease and low-glucose risk. Before increasing insulin, check when the glucose is high. Before reassuring a vomiting patient on an SGLT2 inhibitor, check ketones.

Try it here · Checkpoint 3 of 3

Make your prediction before reading the choices. A first attempt is just a starting point.

Case 26

A 36-year-old woman with type 1 diabetes needs background insulin with a relatively flat profile. Which preparation best matches that role among these choices?

Show answer and explanations for case 26

  1. A. Insulin lispro with the evening meal (Why this does not fit)

    A rapid mealtime dose addresses that meal but does not provide the relatively flat overnight and between-meal coverage requested.

  2. B. Regular insulin once each morning (Why this does not fit)

    Its shorter action and peak do not match the continuous background role required in type 1 diabetes.

  3. C. NPH selected because it has no appreciable peak (Why this does not fit)

    NPH can be used as basal insulin, but it has a more pronounced peak than glargine, so this claim does not match the requested profile.

  4. D. Insulin glargine (Best answer)

    Glargine provides basal coverage with a less pronounced peak than NPH.

Takeaway: Basal insulin covers the intervals between meals.

Case sources: [1] [14]

Apply the mechanisms to clinical decisions

Case 2

A 65-year-old man has newly diagnosed type 2 diabetes, A1C 7.0%, EF 32% and eGFR 48. He cannot tolerate metformin despite careful titration. Which plan best addresses his HF?

Show answer and explanations for case 2

  1. A. Observe without an organ-directed addition because A1C is already near target (Why this does not fit)

    Glycemic control alone does not address his HFrEF outcome risk; an SGLT2 inhibitor can be indicated independently of A1C.

  2. B. Use sitagliptin as the medication intended to reduce HF admissions (Why this does not fit)

    Sitagliptin can lower glucose, but it lacks the requested demonstrated HFrEF outcome benefit.

  3. C. Use pioglitazone as the HF-directed addition (Why this does not fit)

    Pioglitazone causes fluid retention and may worsen HF.

  4. D. Consider an SGLT2 inhibitor with HF evidence despite near-target A1C (Best answer)

    The HF indication is not contingent on metformin use or an elevated A1C.

Takeaway: Organ protection can be indicated independently of A1C.

Case sources: [1] [11]

Case 3

A 62-year-old woman with type 2 diabetes has EF 29%, A1C 8.3% and eGFR 57. Her HF medications are optimized and she is euvolemic. Which diabetes drug best fits her HF risk?

Show answer and explanations for case 3

  1. A. Pioglitazone (Why this does not fit)

    Fluid retention can worsen her reduced-EF heart failure.

  2. B. Glyburide (Why this does not fit)

    It supplies glucose lowering without the requested HF benefit and increases hypoglycemia risk.

  3. C. Dapagliflozin (Best answer)

    DAPA-HF supports benefit in HFrEF; her renal function and volume status permit consideration.

  4. D. Saxagliptin (Why this does not fit)

    Its HF hospitalization warning makes it a poor choice for this priority.

Takeaway: HF changes medication selection.

Case sources: [11] [19] [8] [21]

Case 4

A 68-year-old man with type 2 diabetes has eGFR 26, urine albumin-creatinine ratio 640 mg/g and A1C 8.8%. Empagliflozin is being considered for CKD. Which expectation is most accurate?

Show answer and explanations for case 4

  1. A. Metformin should be started at full dose alongside it (Why this does not fit)

    Metformin is contraindicated below eGFR 30.

  2. B. Kidney benefit can remain useful even though glucose lowering is limited (Best answer)

    Low filtration reduces glycosuric glucose lowering; organ protection and A1C efficacy are distinct.

  3. C. Expect glucose lowering to remain as strong as at normal filtration (Why this does not fit)

    Reduced filtered glucose diminishes the glycosuric glucose effect at this eGFR.

  4. D. Reject empagliflozin for CKD solely because eGFR is below its glucose-lowering threshold (Why this does not fit)

    The glucose-control limitation is distinct from eligibility for the CKD indication.

Takeaway: At low eGFR, plan organ protection and glucose treatment separately.

Case sources: [1] [7] [2]

Case 5

A clinician explains semaglutide to a 60-year-old man with type 2 diabetes and ASCVD. He asks what SUSTAIN-6 itself showed. Which answer is accurate?

Show answer and explanations for case 5

  1. A. Fewer composite major cardiovascular events; similar cardiovascular mortality (Best answer)

    The composite result does not establish a reduction in each component.

  2. B. A statistically significant reduction in cardiovascular death considered separately (Why this does not fit)

    SUSTAIN-6 found similar cardiovascular death rates; the favorable composite cannot be attributed to a proven mortality reduction.

  3. C. A trial designed primarily to compare semaglutide with liraglutide for mortality (Why this does not fit)

    SUSTAIN-6 compared semaglutide with placebo, so it does not establish superiority over liraglutide.

  4. D. A kidney-failure endpoint as the primary outcome (Why this does not fit)

    The primary endpoint was cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, not kidney failure.

Takeaway: Keep composite endpoints separate from their components.

Case sources: [9]

Case 6

A 48-year-old man starts metformin for type 2 diabetes. Fasting glucose improves without weight gain or episodes of sweating and tremor. Which action best explains its glucose effect?

Show answer and explanations for case 6

  1. A. Glucose-independent closure of ATP-sensitive beta-cell potassium channels (Why this does not fit)

    That is the secretagogue mechanism and carries more hypoglycemia risk.

  2. B. Blockade of apical renal SGLT2 (Why this does not fit)

    That describes empagliflozin and related agents.

  3. C. Direct replacement of endogenous insulin (Why this does not fit)

    Metformin is not insulin and cannot replace it in type 1 diabetes.

  4. D. Less hepatic glucose production and greater insulin sensitivity (Best answer)

    Metformin does not directly force beta-cell insulin release.

Takeaway: Metformin reduces glucose supply without forcing secretion.

Case sources: [2]

Case 7

A 43-year-old woman develops mild diarrhea after increasing metformin. BP is 122/76 mmHg, eGFR 91, bicarbonate 25 mEq/L and lactate 1.4 mmol/L. She has no hypoxia or abdominal tenderness. What is the best interpretation?

Show answer and explanations for case 7

  1. A. Metformin-associated lactic acidosis (Why this does not fit)

    Normal lactate, bicarbonate and perfusion argue against lactic acidosis despite a symptom that can occur in both conditions.

  2. B. Diabetic ketoacidosis (Why this does not fit)

    Normal bicarbonate and the absence of a compatible crisis pattern do not support DKA as the explanation for dose-associated diarrhea.

  3. C. Dose-related GI intolerance (Best answer)

    Normal lactate and acid-base status with stable perfusion support the common GI adverse effect.

  4. D. A new contraindication to every metformin formulation (Why this does not fit)

    Common GI intolerance can respond to titration or formulation changes; it does not establish a class-wide permanent contraindication.

Takeaway: Assess the laboratory and clinical pattern rather than the symptom alone.

Case sources: [2]

Case 8

A 71-year-old woman taking metformin for eight years develops distal paresthesias and macrocytic anemia. A1C is stable at 7.1%; hemoglobin is 10.6 g/dL and MCV 108 fL. Which deficiency should be assessed?

Show answer and explanations for case 8

  1. A. Folate (Why this does not fit)

    Folate deficiency can produce macrocytosis, but the neuropathy and long metformin exposure particularly warrant a B12 assessment.

  2. B. Vitamin B12 (Best answer)

    Long-term metformin can reduce B12 and contribute to anemia and neuropathy.

  3. C. Iron (Why this does not fit)

    Iron deficiency typically causes microcytosis and does not adequately account for this macrocytic neurologic presentation.

  4. D. Vitamin K (Why this does not fit)

    Vitamin K deficiency affects coagulation rather than characteristically producing macrocytic anemia with distal paresthesias.

Takeaway: Do not label every neuropathy in diabetes as diabetic neuropathy.

Case sources: [2]

Case 10

A 67-year-old woman on metformin will receive iodinated IV contrast. Her stable eGFR is 42. The facility follows US product labeling. Which plan fits that policy?

Show answer and explanations for case 10

  1. A. Continue because only eGFR below 30 ever matters for contrast (Why this does not fit)

    The label's contrast precaution is broader than the baseline absolute renal contraindication.

  2. B. Permanently discontinue metformin after any contrast dose (Why this does not fit)

    A temporary hold with reassessment does not imply permanent loss of eligibility.

  3. C. Start glyburide during fasting without glucose monitoring (Why this does not fit)

    Fasting plus a secretagogue adds avoidable hypoglycemia risk.

  4. D. Hold at or before contrast and reassess renal function after 48 hours before restarting (Best answer)

    The eGFR 30 to 60 group is included in the label's contrast precaution.

Takeaway: Specify both the patient's risk and the protocol being applied.

Case sources: [2]

Case 11

A 57-year-old man becomes sweaty and confused after missing lunch. Glucose is 41 mg/dL, insulin and C-peptide are increased, and a sulfonylurea screen is positive. What action caused his hypoglycemia?

Show answer and explanations for case 11

  1. A. Inhibition of intestinal carbohydrate digestion alone (Why this does not fit)

    Acarbose alone has low hypoglycemia risk and would not explain a positive sulfonylurea screen.

  2. B. Exogenous insulin without endogenous secretion (Why this does not fit)

    Injected insulin would not directly explain increased C-peptide and the positive drug screen.

  3. C. Closure of beta-cell ATP-sensitive potassium channels (Best answer)

    The resulting depolarization and calcium entry stimulate endogenous insulin release despite low glucose.

  4. D. Opening those channels to suppress insulin (Why this does not fit)

    Opening the channels hyperpolarizes the cell and would reduce secretion.

Takeaway: C-peptide and exposure distinguish endogenous from injected insulin.

Case sources: [3]

Case 12

A 79-year-old woman with CKD and poor appetite has hypoglycemia while taking glipizide. A trainee says it is eliminated unchanged by the kidney just like every sulfonylurea. Which correction is best?

Show answer and explanations for case 12

  1. A. Glipizide is excreted almost entirely unchanged, so its hepatic metabolism is unimportant (Why this does not fit)

    Glipizide undergoes substantial hepatic metabolism; the trainee's unchanged renal-excretion explanation is incorrect.

  2. B. Hepatic metabolism predominates; CKD and poor intake still raise hypoglycemia risk (Best answer)

    The actual metabolic pathway does not remove the clinical susceptibility.

  3. C. Its mostly inactive metabolites eliminate hypoglycemia risk in CKD (Why this does not fit)

    The active parent drug still stimulates insulin release, and poor intake and CKD increase clinical susceptibility.

  4. D. Stopping glipizide ensures hypoglycemia cannot recur later that day (Why this does not fit)

    Drug effects can outlast a glucose correction or the most recent dose, so this patient needs continued assessment.

Takeaway: Correct the mechanism without minimizing the risk.

Case sources: [3]

Case 13

A 74-year-old man on a sulfonylurea awakens after IV dextrose for glucose 29 mg/dL. Three hours later he again becomes confused at glucose 40. What best explains recurrence?

Show answer and explanations for case 13

  1. A. Persistent drug-stimulated insulin release after transient glucose correction (Best answer)

    Dextrose treats the immediate low but does not remove the secretagogue effect; monitored ongoing treatment is needed.

  2. B. Postabsorptive fasting alone after the secretagogue effect has ended (Why this does not fit)

    The recurrent severe low shortly after dextrose while exposed to a sulfonylurea supports ongoing drug-stimulated insulin release.

  3. C. Delayed absorption of a large injected insulin dose (Why this does not fit)

    Exogenous insulin can produce recurrent lows, but no injection is described; the stated sulfonylurea exposure is the stronger explanation.

  4. D. New autonomous insulin secretion from an insulinoma (Why this does not fit)

    An insulinoma is a differential consideration in unexplained endogenous hyperinsulinemia, but the active secretagogue is a direct explanation here.

Takeaway: A corrected glucose value is not proof the cause has ended.

Case sources: [3] [15]

Case 14

A 52-year-old woman using linagliptin has modest A1C improvement, stable weight and no lows. Which mechanism explains increased insulin secretion with low intrinsic hypoglycemia risk?

Show answer and explanations for case 14

  1. A. Direct SUR1 binding with glucose-independent insulin release (Why this does not fit)

    That sulfonylurea pathway carries greater intrinsic hypoglycemia risk and does not describe linagliptin.

  2. B. PPAR-gamma activation that increases peripheral insulin sensitivity (Why this does not fit)

    That is the TZD pathway rather than the incretin-preserving action asked about in this patient.

  3. C. Inhibition of proximal tubular glucose reabsorption (Why this does not fit)

    That is an SGLT2 mechanism, which lowers glucose through urinary loss rather than increased incretin-mediated secretion.

  4. D. Preservation of endogenous incretins with glucose-dependent action (Best answer)

    DPP-4 inhibition prolongs incretin signaling rather than forcing secretion independently of glucose.

Takeaway: Glucose dependence is the useful discriminator.

Case sources: [4]

Case 15

A 76-year-old man with type 2 diabetes and eGFR 23 needs a modest oral glucose-lowering addition after individualized review. Which listed drug does not require renal dose adjustment?

Show answer and explanations for case 15

  1. A. Sitagliptin (Why this does not fit)

    Sitagliptin needs renal dose adjustment at this eGFR, unlike linagliptin.

  2. B. Saxagliptin (Why this does not fit)

    Saxagliptin requires 2.5 mg daily when eGFR is below 45, rather than unrestricted usual dosing. Linagliptin does not require renal dose adjustment.

  3. C. Linagliptin (Best answer)

    Its label does not require dose adjustment for renal impairment.

  4. D. Metformin (Why this does not fit)

    It is contraindicated at this eGFR.

Takeaway: Renal dosing varies within and between classes.

Case sources: [4] [2] [1] [21]

Case 16

A 56-year-old woman gains 4 kg and develops orthopnea six weeks after pioglitazone initiation. Examination shows raised jugular venous pressure, ankle edema and crackles. Creatinine and albuminuria are unchanged. What is the likely medication effect?

Show answer and explanations for case 16

  1. A. Progressive protein-losing nephropathy as the best medication explanation (Why this does not fit)

    Stable albuminuria and the timing after pioglitazone favor drug-related fluid retention rather than newly worsening protein loss.

  2. B. Sodium and fluid retention associated with pioglitazone (Best answer)

    The timing and systemic congestion fit the TZD warning and require treatment reassessment.

  3. C. Osmotic diuresis caused by pioglitazone (Why this does not fit)

    Pioglitazone is not an SGLT2 inhibitor; the weight gain and congestion indicate retention rather than osmotic volume loss.

  4. D. Isolated chronic venous insufficiency (Why this does not fit)

    Leg edema alone could fit venous disease, but it does not explain orthopnea, raised JVP and pulmonary crackles.

Takeaway: New edema after a TZD is a medication safety signal.

Case sources: [8]

Case 17

A 64-year-old woman taking pioglitazone sustains a distal radius fracture after a standing-height fall. Calcium and vitamin D are normal. Which drug-related issue warrants review?

Show answer and explanations for case 17

  1. A. TZD-associated increased fracture risk (Best answer)

    Pioglitazone can increase fracture risk, particularly in women, even when these laboratory values are normal.

  2. B. Metformin-associated vitamin B12 deficiency as the direct explanation (Why this does not fit)

    The patient is taking pioglitazone, and the stem describes skeletal fragility without a B12-related neurologic pattern.

  3. C. A direct consequence of renal glucose wasting from pioglitazone (Why this does not fit)

    Pioglitazone acts through PPAR-gamma rather than SGLT2, so that proposed mechanism belongs to a different class.

  4. D. A proven hypoglycemic fall caused by pioglitazone alone (Why this does not fit)

    No low glucose is documented, and pioglitazone alone has low intrinsic hypoglycemia risk; the established fracture association is more relevant.

Takeaway: A medication can affect injury risk without causing the fall.

Case sources: [8]

Case 18

A 49-year-old man reports early fullness and mild nausea two weeks after starting semaglutide. He has no persistent abdominal pain, vomiting or tenderness. What mechanism best fits?

Show answer and explanations for case 18

  1. A. Increased urinary glucose excretion as the primary action (Why this does not fit)

    That is the SGLT2 mechanism, not semaglutide's principal pathway.

  2. B. Intestinal carbohydrate malabsorption from alpha-glucosidase inhibition (Why this does not fit)

    That acarbose mechanism commonly causes flatulence. It does not describe semaglutide's appetite and gastric effects.

  3. C. Fat malabsorption from pancreatic lipase inhibition (Why this does not fit)

    That describes orlistat rather than a GLP-1 receptor agonist.

  4. D. Increased satiety signaling and delayed gastric emptying (Best answer)

    These expected pharmacologic actions can explain early satiety and mild nausea after initiation.

Takeaway: Expected GI effects and concerning abdominal symptoms need different assessments.

Case sources: [5] [1]

Case 19

A 40-year-old woman with type 2 diabetes wants semaglutide. Her mother has MEN2-associated medullary thyroid carcinoma. Which recommendation fits the label?

Show answer and explanations for case 19

  1. A. Obtain a normal TSH before starting semaglutide (Why this does not fit)

    TSH assesses thyroid hormone regulation; it does not exclude C-cell disease or waive the family-MTC contraindication.

  2. B. Start at a lower dose with annual thyroid ultrasonography (Why this does not fit)

    Dose reduction and ultrasound surveillance do not replace compliance with a listed contraindication.

  3. C. Avoid semaglutide because of the family MTC/MEN2 history (Best answer)

    This is a listed contraindication even though human causation from rodent C-cell findings is uncertain.

  4. D. Defer the decision until the patient develops a palpable thyroid nodule (Why this does not fit)

    The family history already establishes the label contraindication; a nodule need not develop first.

Takeaway: Use the specific thyroid diagnosis, not the word thyroid alone.

Case sources: [5]

Case 20

A 45-year-old man has improved A1C and reduced appetite after tirzepatide initiation. Which two receptors are directly activated?

Show answer and explanations for case 20

  1. A. PPAR-gamma and GIP receptors (Why this does not fit)

    PPAR-gamma activation belongs to TZDs, not tirzepatide.

  2. B. GIP and GLP-1 receptors (Best answer)

    Tirzepatide is a dual incretin receptor agonist.

  3. C. GLP-1 and insulin receptors (Why this does not fit)

    It stimulates insulin secretion through incretin signaling rather than directly acting as insulin.

  4. D. GLP-1 and glucagon receptors (Why this does not fit)

    Tirzepatide activates GIP and GLP-1 receptors. Glucagon receptor agonism is not one of its two labeled targets.

Takeaway: Dual incretin action is distinct from insulin replacement.

Case sources: [6]

Case 21

A 31-year-old woman taking an oral hormonal contraceptive starts tirzepatide. Which counseling is supported by its label?

Show answer and explanations for case 21

  1. A. Add barrier protection or use a nonoral method for four weeks after starting and each dose increase (Best answer)

    Delayed gastric emptying can affect oral contraceptive effectiveness during these intervals.

  2. B. Double the contraceptive dose without consultation (Why this does not fit)

    The label recommends a nonoral method or added barrier protection rather than self-directed dose doubling.

  3. C. Use backup contraception for the first week only (Why this does not fit)

    The label specifies four weeks after initiation and after each dose escalation.

  4. D. Use backup after initiation but omit it after later dose increases (Why this does not fit)

    The label also specifies a four-week interval after every dose escalation.

Takeaway: Administration route does not eliminate drug interactions.

Case sources: [6]

Case 22

A 69-year-old man develops glans itching after empagliflozin. He has localized erythema, marked glucosuria and no fever, crepitus, severe pain or pyuria. What mechanism predisposes to this problem?

Show answer and explanations for case 22

  1. A. Immune suppression from inhibition of leukocyte proliferation (Why this does not fit)

    Empagliflozin inhibits renal glucose transport; generalized leukocyte suppression is not the drug mechanism explaining the local mycosis.

  2. B. Ascending bacterial infection of the renal parenchyma (Why this does not fit)

    Pyelonephritis would usually produce systemic or upper urinary findings; local glans itching and glucosuria favor a genital mycotic complication.

  3. C. Necrotizing infection of the perineal fascia (Why this does not fit)

    Severe pain, systemic illness and tissue destruction would prompt emergency evaluation; they are absent from this localized presentation.

  4. D. Urinary glucose loss creates conditions favoring genital Candida (Best answer)

    The localized presentation fits a mycotic complication of glycosuria.

Takeaway: Distinguish common local mycosis from invasive infection.

Case sources: [7]

Case 23

A 58-year-old woman taking an SGLT2 inhibitor has fever, severe perineal pain and swelling with dusky skin. BP is 90/56 mmHg and examination suggests tissue crepitus. What is the best next plan?

Show answer and explanations for case 23

  1. A. Treat presumed uncomplicated genital candidiasis with topical antifungal alone (Why this does not fit)

    Localized candidiasis would not explain hypotension, severe pain, dusky tissue and possible crepitus.

  2. B. Arrange routine outpatient evaluation for a lower urinary tract infection (Why this does not fit)

    The systemic instability and perineal tissue findings demand emergency source-control assessment rather than routine cystitis care.

  3. C. Urgent surgical assessment, resuscitation and broad antibiotics; stop the SGLT2 inhibitor (Best answer)

    This is concerning for necrotizing perineal infection and cannot be managed as simple yeast irritation.

  4. D. Give oral antibiotics and reassess in two days without surgical input (Why this does not fit)

    Possible necrotizing infection can progress rapidly, so delayed reassessment without surgical evaluation is inadequate.

Takeaway: Severe perineal pain with systemic illness requires urgent assessment.

Case sources: [7]

Case 24

A 50-year-old man with type 2 diabetes taking empagliflozin has vomiting after prolonged fasting. Glucose is 174 mg/dL, beta-hydroxybutyrate 5.1 mmol/L, bicarbonate 12 mEq/L and venous pH 7.23. Which diagnosis best fits?

Show answer and explanations for case 24

  1. A. Starvation ketosis as the most likely sole explanation (Why this does not fit)

    Fasting can cause ketosis, but marked ketonemia and acidosis in a patient with diabetes taking an SGLT2 inhibitor require treating suspected euglycemic DKA.

  2. B. Euglycemic diabetic ketoacidosis (Best answer)

    Ketosis and metabolic acidosis in this setting establish the concern despite modest glucose.

  3. C. Hyperosmolar hyperglycemic state (Why this does not fit)

    The modest glucose and prominent ketoacidosis do not meet the pattern of HHS.

  4. D. Isolated metformin-associated lactic acidosis (Why this does not fit)

    He is not described as taking metformin, and the markedly increased ketone level is central.

Takeaway: Glucose alone cannot exclude DKA.

Case sources: [7] [13]

Case 25

A 60-year-old woman taking canagliflozin is scheduled for elective surgery next week. She is well and eating normally. Which instruction best reduces perioperative ketoacidosis risk?

Show answer and explanations for case 25

  1. A. Stop canagliflozin three days before scheduled surgery (Best answer)

    ADA guidance uses three days for this drug and four for ertugliflozin.

  2. B. Hold canagliflozin only on the morning of surgery (Why this does not fit)

    The recommended preoperative interval is longer because ketoacidosis risk can persist after the last dose.

  3. C. Hold canagliflozin the evening before surgery (Why this does not fit)

    An overnight hold is shorter than the recommended three-day interval.

  4. D. Continue canagliflozin and monitor glucose alone during fasting (Why this does not fit)

    Near-normal glucose cannot exclude perioperative ketoacidosis. Planned withholding reduces this risk.

Takeaway: Plan SGLT2 withholding before fasting begins.

Case sources: [14]

Case 27

A 28-year-old man with type 1 diabetes has vomiting, dehydration, glucose 462 mg/dL, beta-hydroxybutyrate 6.2 mmol/L, pH 7.12 and potassium 4.8 mEq/L. Fluids and close monitoring are underway. Which insulin strategy fits standard IV treatment?

Show answer and explanations for case 27

  1. A. Give subcutaneous glargine as the sole immediate crisis treatment (Why this does not fit)

    Basal insulin alone does not provide the titratable standard IV strategy needed for this patient's acidosis and evolving physiology.

  2. B. Start IV lispro U-200 using the same concentration as regular insulin (Why this does not fit)

    U-200 lispro must not be given intravenously; formulation restrictions remain essential even though U-100 has labeled IV use.

  3. C. Titrated IV regular insulin with electrolyte and glucose monitoring (Best answer)

    This treats ketogenesis while allowing adjustment to the evolving physiology.

  4. D. Wait for glucose normalization with fluids before giving any insulin (Why this does not fit)

    Fluid replacement is necessary but does not replace insulin's suppression of ketogenesis in this presentation.

Takeaway: DKA therapy needs insulin and coordinated electrolyte care.

Case sources: [13] [17]

Case 28

A 33-year-old woman with DKA has potassium 3.1 mmol/L before insulin treatment. Which sequence is appropriate?

Show answer and explanations for case 28

  1. A. Begin insulin and replace potassium only if an arrhythmia occurs (Why this does not fit)

    Insulin can rapidly worsen the initial potassium deficit; waiting for an arrhythmia misses preventive correction.

  2. B. Start potassium replacement and delay insulin until potassium exceeds 3.5 mmol/L (Best answer)

    Insulin shifts potassium intracellularly and could worsen dangerous depletion.

  3. C. Withhold potassium because serum values always exceed total-body stores in DKA (Why this does not fit)

    The measured potassium is already low despite the usual outward shift, indicating a particularly important deficit.

  4. D. Start bicarbonate alone and postpone potassium reassessment (Why this does not fit)

    Bicarbonate is not a substitute for potassium replacement and can aggravate intracellular potassium shifting.

Takeaway: Low potassium changes the order of DKA treatment.

Case sources: [13]

Case 29

A 73-year-old woman eating regular meals in hospital has type 2 diabetes previously treated with basal-bolus insulin. After switching to correction-only insulin, glucose repeatedly ranges from 230 to 290 mg/dL. What is the best adjustment?

Show answer and explanations for case 29

  1. A. Resume basal and meal insulin on a schedule plus corrections (Best answer)

    Persistent hyperglycemia reflects missing background and meal coverage.

  2. B. Keep correction-only therapy indefinitely despite the pattern (Why this does not fit)

    Repeated reactive doses do not adequately replace the scheduled components she needs.

  3. C. Add pioglitazone for an immediate effect (Why this does not fit)

    Its gradual onset does not address the inpatient pattern promptly.

  4. D. Use scheduled prandial insulin without replacing basal insulin (Why this does not fit)

    She previously required basal-bolus treatment. Prandial doses alone leave her background insulin requirement untreated.

Takeaway: Correction insulin supplements a needed regimen.

Case sources: [14]

Case 30

A 46-year-old man with type 1 diabetes has repeated nocturnal glucose values below 50 mg/dL and no longer notices his usual warning symptoms. He has no orthostatic symptoms. What best explains this change?

Show answer and explanations for case 30

  1. A. Irreversible diabetic autonomic neuropathy proven by this history alone (Why this does not fit)

    Recurrent antecedent lows can cause a potentially reversible change in awareness; the history alone does not prove structural autonomic neuropathy.

  2. B. Measurement artifact as the leading explanation for all nocturnal lows (Why this does not fit)

    Sensor artifacts merit confirmation when discordant, but recurrent antecedent hypoglycemia with loss of usual warnings supports impaired awareness and requires active reassessment.

  3. C. New adrenal insufficiency as the established cause (Why this does not fit)

    Adrenal insufficiency can predispose to hypoglycemia, but the history supplies no supporting systemic findings and specifically fits antecedent-low-related loss of awareness.

  4. D. Hypoglycemia-associated autonomic failure after recurrent lows (Best answer)

    Antecedent hypoglycemia can attenuate counterregulation and awareness; avoidance and regimen revision may improve it.

Takeaway: Recurrent lows can make the next low harder to recognize.

Case sources: [15]

Case 31

A 66-year-old man develops prominent flatulence after acarbose is added for postprandial hyperglycemia. The abdomen is soft without focal tenderness. Which mechanism explains the gas?

Show answer and explanations for case 31

  1. A. Pancreatic lipase inhibition causing fat malabsorption (Why this does not fit)

    That is the orlistat mechanism; acarbose instead delays carbohydrate digestion and increases fermentable substrate.

  2. B. Proximal tubular glucose wasting (Why this does not fit)

    The SGLT2 mechanism does not account for acarbose's intestinal fermentation-related gas.

  3. C. Colonic fermentation of carbohydrate whose digestion was delayed (Best answer)

    Alpha-glucosidase inhibition increases carbohydrate delivery to intestinal bacteria.

  4. D. Inhibition of DPP-4 causing accumulation of endogenous incretins (Why this does not fit)

    That mechanism belongs to gliptins and does not explain increased carbohydrate delivery to colonic bacteria.

Takeaway: Acarbose's site of action explains its GI tolerability.

Case sources: [16]

Case 32

A 63-year-old woman taking acarbose and basal insulin is alert but tremulous with glucose 58 mg/dL. She can swallow safely. Which oral rescue is most appropriate?

Show answer and explanations for case 32

  1. A. Sucrose as the preferred rapid equivalent (Why this does not fit)

    Acarbose delays sucrose digestion, whereas free glucose can be absorbed without that blocked step.

  2. B. Glucose tablets (Best answer)

    Glucose absorption does not require the disaccharide digestion inhibited by acarbose.

  3. C. A complex-starch snack alone as the fastest rescue (Why this does not fit)

    Starch requires digestion and is less suitable than directly absorbable glucose for prompt treatment of this symptomatic low.

  4. D. Withhold the next insulin dose but give no carbohydrate now (Why this does not fit)

    Later dose adjustment may be needed, but it does not correct the current symptomatic hypoglycemia.

Takeaway: Use glucose when acarbose is present.

Case sources: [16] [15]

Case 33

A 54-year-old patient with type 2 diabetes taking canagliflozin arrives for elective surgery after fasting. Glucose is 146 mg/dL, beta-hydroxybutyrate 5.4 mmol/L, pH 7.24, bicarbonate 13 mmol/L and potassium 4.3 mmol/L. What is the best immediate plan?

Show answer and explanations for case 33

  1. A. Postpone elective surgery, stop canagliflozin and treat ketoacidosis with fluids, insulin, dextrose and electrolyte monitoring (Best answer)

    The ketones and acidosis establish an acute metabolic problem despite modest glucose; dextrose permits needed insulin while avoiding hypoglycemia.

  2. B. Proceed with surgery because glucose is below 180 mg/dL (Why this does not fit)

    Perioperative safety cannot be judged by glucose alone when significant ketoacidosis is present.

  3. C. Give dextrose alone and wait for ketones to disappear (Why this does not fit)

    Glucose support may be needed, but insulin is necessary to suppress ketogenesis in SGLT2-associated DKA.

  4. D. Hold canagliflozin and send the patient home without active treatment (Why this does not fit)

    Withholding the drug does not immediately resolve established acidosis or replace monitored treatment.

Takeaway: Preventing perioperative DKA and treating established DKA are different decisions.

Case sources: [13] [14] [7]

Case 34

A patient with type 2 diabetes taking semaglutide reports less hunger and smaller meals, with gradual weight loss. There is no diarrhea or glucosuria. Which mechanism most directly contributes to reduced energy intake?

Show answer and explanations for case 34

  1. A. Blockade of pancreatic lipase causing fat malabsorption (Why this does not fit)

    That is the orlistat pathway; the described reduced hunger without malabsorptive symptoms fits semaglutide's appetite effects.

  2. B. Inhibition of intestinal alpha-glucosidase causing carbohydrate fermentation (Why this does not fit)

    That is the acarbose pathway and is more associated with gas than the reported reduction in hunger.

  3. C. Proximal tubular glucose wasting (Why this does not fit)

    That SGLT2 mechanism causes urinary energy loss, but semaglutide does not act through the renal transporter.

  4. D. GLP-1 receptor-mediated appetite and satiety effects (Best answer)

    Semaglutide can reduce appetite and food intake; the patient's smaller meals fit this mechanism rather than nutrient loss.

Takeaway: Different weight effects can arise from lower intake, malabsorption or urinary energy loss.

Case sources: [5] [1]

Sources

  1. ADA Standards of Care 2026. Pharmacologic approaches to glycemic treatment (2026)

    Comorbidity-directed selection independent of A1C or prior metformin, severe hyperglycemia and combination selection; relevant full-text recommendations read in the identical PMC article.

  2. Metformin hydrochloride. Official prescribing information

    Renal thresholds, contrast instructions, B12, GI effects, mechanism and lactic acidosis risk.

  3. Glipizide. Official prescribing information

    Hepatic metabolism, largely inactive metabolites, insulin secretion and hypoglycemia.

  4. Linagliptin. Official prescribing information

    DPP-4 mechanism, renal dosing, safety and glucose-dependent action.

  5. Ozempic. Official prescribing information

    Semaglutide mechanism, MTC/MEN2 contraindication, GI effects and retinopathy precaution.

  6. Mounjaro. Official prescribing information

    Dual GIP/GLP-1 action and oral contraceptive counseling.

  7. Jardiance. Official prescribing information

    SGLT2 renal physiology, reduced glycemic efficacy at low eGFR, genital infection, volume depletion, ketoacidosis and Fournier gangrene.

  8. Pioglitazone. Official prescribing information

    PPAR-gamma, fluid retention, NYHA III/IV initiation contraindication, fractures and bladder cancer caution.

  9. SUSTAIN-6. Semaglutide and cardiovascular outcomes in type 2 diabetes (2016)

    Composite MACE reduction did not establish cardiovascular death reduction in this trial.

  10. LEADER. Liraglutide and cardiovascular outcomes in type 2 diabetes (2016)

    Agent-specific MACE and cardiovascular death evidence.

  11. DAPA-HF. Dapagliflozin in HFrEF (2019)

    Heart failure outcomes with and without diabetes.

  12. FLOW. Semaglutide in type 2 diabetes and chronic kidney disease (2024)

    Kidney outcome benefit prevents an outdated GLP-1 versus kidney false dichotomy.

  13. Hyperglycemic crises in adults with diabetes. International consensus report (2024)

    DKA including euglycemic presentations, potassium before insulin, dextrose during treatment and monitoring.

  14. ADA Standards of Care 2026. Diabetes care in the hospital (2026)

    Basal/prandial/correction insulin, perioperative metformin and SGLT2 precautions.

  15. ADA Standards of Care 2026. Glycemic goals and hypoglycemia (2026)

    Hypoglycemia rescue, recurrent lows, awareness recovery and individualized targets.

  16. Acarbose. Official prescribing information

    Brush-border carbohydrate digestion, flatulence and glucose rather than sucrose for hypoglycemia.

  17. Humalog. Official prescribing information

    Lispro U-100 intravenous use versus formulation restrictions.

  18. FDA prescribing information: rosiglitazone maleate and glimepiride tablets (2015)

    Historical US approved product labeling issued September 2015 and archived under an FDA 2016 path, refuting universal withdrawal; continuing heart failure warning. Does not establish current retail availability.

  19. FDA heart failure warnings for saxagliptin and alogliptin (2016)

    FDA 2016 warning about saxagliptin and alogliptin, read through the official indexed document because direct retrieval returned a soft 404; saxagliptin warning also verified against source 21.

  20. Utah Poison Control Fast Facts: Octreotide (2022-08-17)

    Suppression of endogenous insulin release in sulfonylurea-associated recurrent hypoglycemia and need for observation. Does not adopt the handout's absolute no-side-effects statement.

  21. Saxagliptin prescribing information

    Renal dose of 2.5 mg daily at eGFR below 45; SAVOR heart-failure hospitalization warning.

Return to lesson title

Search Bone Wizardry

Quick links
↑ ↓ Navigate Enter Open Esc CloseBrowse the library ↗